Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Clinical trial NCT06082167 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06082167
- Sponsor
- Exelixis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-07
- Primary completion
- 2028-08-01
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.